Toronto, Ontario–(Newsfile Corp. – July 5, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), announced today that it has reached an agreement...
Toronto, Ontario–(Newsfile Corp. – May 23, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), is announcing that it has appointed David Posner...
Toronto, Ontario–(Newsfile Corp. – May 8, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), is announcing that the Ontario Securities Commission has...
Toronto, Ontario–(Newsfile Corp. – April 14, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research,...
PharmaDrug is positioning to become a leader of DMT-based therapeutics for ocular disease and neuropsychiatric conditions Toronto, Ontario–(Newsfile Corp. – February 22, 2023) – PharmaDrug Inc....
Toronto, Ontario–(Newsfile Corp. – February 13, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research,...
Toronto, Ontario–(Newsfile Corp. – January 31, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research,...
Completes clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance Optimized manufacturing processes substantially increases drug product yield To initiate ICH-compliant stability, forced degradation and drug product...
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4,...
Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substance Clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled for delivery in...